Bavarian Nordic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.06.19	Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs (GlobeNewswire)
19.06.19	Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine (GlobeNewswire)
05.06.19	Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma (GlobeNewswire)
22.05.19	Bavarian Nordic Announces Interim Results for the First Three Months of 2019 (GlobeNewswire)
14.05.19	Bavarian Nordic to Host First Quarter 2019 Results Conference Call (GlobeNewswire)
28.03.19	Bavarian Nordic A/S – Notice Convening Ordinary General Meeting (GlobeNewswire)
21.03.19	Bavarian Nordic Announces Annual Report 2018 (GlobeNewswire)
21.02.19	Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen (GlobeNewswire)
25.01.19	Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial (GlobeNewswire)
18.01.19	Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine (GlobeNewswire)
21.12.18	Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine (GlobeNewswire)
09.11.18	Bavarian Nordic Announces Interim Results for the First Nine Months of 2018 (GlobeNewswire)
02.11.18	Bavarian Nordic to Host Third Quarter 2018 Results Conference Call (GlobeNewswire)
02.11.18	Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers (GlobeNewswire)
01.11.18	Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma (GlobeNewswire)
19.09.18	Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox Cases (GlobeNewswire)
18.09.18	Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer (GlobeNewswire)
21.08.18	Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise (GlobeNewswire)
16.08.18	Bavarian Nordic Announces First Half 2018 Results (GlobeNewswire)
16.08.18	Bavarian Nordic Announces First Half 2018 Results (GlobeNewswire)
09.08.18	Bavarian Nordic Granted EUR 30 Million Loan from The European Investment Bank (GlobeNewswire)
08.08.18	Bavarian Nordic to Host First Half 2018 Results Conference Call (GlobeNewswire)
11.07.18	Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer (GlobeNewswire)
31.05.18	Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer (GlobeNewswire)
24.05.18	Bavarian Nordic Announces Interim Results for the First Three Months of 2018 (GlobeNewswire)
16.05.18	Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
16.05.18	Bavarian Nordic to Host First Quarter 2018 Results Conference Call (GlobeNewswire)
02.05.18	Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma (GlobeNewswire)
17.04.18	Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 2018 (GlobeNewswire)
27.03.18	Bavarian Nordic to Present at Needham & Company's 17th Annual Healthcare Conference in New York City (GlobeNewswire)
26.03.18	Bavarian Nordic A/S - Notice Convening Ordinary General Meeting (GlobeNewswire)
16.03.18	Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus (GlobeNewswire)
12.03.18	Bavarian Nordic Announces Annual Report 2017 (GlobeNewswire)
08.03.18	Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer (GlobeNewswire)
07.03.18	Bavarian Nordic to Host Full Year 2017 Results Conference Call (GlobeNewswire)
06.03.18	Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine (GlobeNewswire)
26.02.18	Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers (GlobeNewswire)
06.02.18	Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine (GlobeNewswire)
31.01.18	Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen (GlobeNewswire)
19.01.18	Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis (GlobeNewswire)
21.11.17	Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine (GlobeNewswire)
09.11.17	Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine (GlobeNewswire)
08.11.17	Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 (GlobeNewswire)
27.09.17	Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government (GlobeNewswire)
21.09.17	Bavarian Nordic Provides Update on its Universal RSV Vaccine (GlobeNewswire)
14.09.17	Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer (GlobeNewswire)
14.09.17	Bavarian Nordic to Host Capital Markets Day in New York City (GlobeNewswire)
11.09.17	Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress (GlobeNewswire)
25.08.17	Bavarian Nordic Announces First Half 2017 Results (GlobeNewswire)
22.08.17	Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc. (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

22.08.24		Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen
22.08.24		Ausblick: Bavarian Nordic legt Quartalsergebnis vor
20.08.24		Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an
23.08.22		Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

22.08.24

Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen

22.08.24

Ausblick: Bavarian Nordic legt Quartalsergebnis vor

20.08.24

Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an

23.08.22

Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	28.76	3.71 %	K V
Swiss Life Hldg	711.60	1.72 %	K V
Swiss Re	132.75	1.18 %	K V
Zurich Insur Gr	543.00	0.78 %	K V
Holcim	87.92	0.64 %	K V
Logitech Intl	74.54	-0.67 %	K V
Alcon	76.32	-0.75 %	K V
Geberit	509.60	-0.97 %	K V
Sika	213.20	-1.20 %	K V
CieFinRichemont	135.35	-1.85 %	K V

Nachrichten zu Bavarian Nordic A/S

Aktien Top/Flop

Bavarian Nordic Peer Group Nachrichten

Meistgelesene Nachrichten